This chemical is primarily utilized in the field of targeted protein degradation, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). It serves as a key component in designing molecules that can selectively degrade disease-causing proteins by recruiting them to the ubiquitin-proteasome system. Its structure allows for effective binding to E3 ubiquitin ligases, enabling the targeted degradation of specific proteins of interest. This application is highly relevant in drug discovery and therapeutic research, especially for treating cancers, neurodegenerative diseases, and other conditions driven by aberrant protein activity. Its incorporation into PROTACs offers a promising approach for addressing traditionally "undruggable" targets.